




Objective: To investigate the correlation of the immunoassay and chromatography method for quantitative measurement of two antiepileptic 
drugs (AED), carbamazepine (CBZ) and phenytoin (PHT) and determination of relation between the CBZ and it’s metabolite carbamazepine 10,11-
epoxide (CBZ-E). Additionally we investigated whether there is a di4 erence in the determination of serum concentration of CBZ and PHT when mea-
sured in two di4 erent labs by high performance liquid chromatography (HPLC).
Materials and methods: This study was carried out on 102 blood samples (72 CBZ and 30 PHT) collected from epileptic outpatients. Plasma con-
centrations of CBZ and PHT were determined by validated HPLC (Shimadzu and Agilent) and the CEDIA-immunoassay method.
Results: The correlations of serum concentrations of CBZ between CEDIA and HPLC1 and between CEDIA and HPLC2 were good (R = 0.97 for both 
techniques). Even better correlation was found between concentrations of CBZ measured by the two HPLC systems (R = 0.99). Similar, for PHT, we 
found good correlation between CEDIA and the two systems of HPLC (HPLC1 and HPLC2, R = 0.98) and between the two systems of HPLC of R =0.98. 
The moderate correlation coe>  cient was found between serum concentrations of CBZ and its metabolite CBZ-E, measured in two labs by di4 erent 
HPLC (R = 0.49 and 0.43, respectively; P < 0.001).
Conclusion: We observed good correlation for estimation of CBZ and PHT concentration obtained by means the immunoassay and two di4 erent 
HPLC. The possibility of measurement of CBZ-E could be advantage of chromatography in comparison with immunoassay.
Key words: carbamazepine; phenytoine; HPLC; immunoassay
Received: July 9, 2010 Accepted: September 7, 2010
Comparison between the immunoassay and high performance liquid 
chromatography for therapeutic monitoring of carbamazepine and phenytoine
Shaip Krasniqi1,2*, Markus Zeitlinger2, Ste4 en Bauer3
1Institute of Clinical Pharmacology, University Clinical Center of Kosova, Prishtina, Kosovo
2Department of Clinical Pharmacology, Medical University of Vienna
3Central Institute for Lab Medicine and Biochemistry - University Clinical Center “Charité” -Berlin
*Corresponding author: shbk71@gmail.com
Introduction
Antiepileptic drugs are characterized with impor-
tant inter-and/or intra-individual variation in phar-
macokinetics and diP erent susceptibility to adver-
se reaction (1). The clinical eP ect of many antiepi-
leptic drugs correlates better with blood levels 
than with doses (2, 3).
Up until approximately 20 years ago, anti-epileptic 
therapeutics were restricted to very few drugs that 
were developed in the W rst half of the 20th centu-
ry, so called old antiepileptic drugs. A relatively 
small therapeutic index and the desirability to 
guide the therapy with therapeutic drug monitor-
ing (TDM) characterize the antiepileptics of the 
old, but also of the newer generation (4,5).
The old antiepileptic drugs (AED) still remain valu-
able in the epilepsy treatment, and the optimiza-
tion of therapy with these drugs through TDM is 
imperative.
Carbamazepine (CBZ) is considered the W rst-line 
anticonvulsant for the treatment of generalized to-
nic-clonic and complex partial seizures. Its use is 
complicated by variable absorption, auto-inducti-
on, hetero-induction of the CYP3A4 isoenzyme 
and its active metabolite carbamazepine-10,11-
epoxide (EPO-CBZ) (6). The pharmacologic activity 
of the metabolite CBZ-E is similar to that of CBZ (7).
PHT is a primary anticonvulsant drug for the prop-
hylaxis and treatment of generalized tonic-clonic 
and partial seizures. PHT exhibits nonlinear phar-
macokinetics in the therapeutic range. All these 
properties of antiepileptic drugs argue the use of 
TDM (8,9), as the interpretation of plasma levels of 
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AED in the light of the clinical situation of epileptic 
patients can markedly inb uence dose optimisation 
of these drugs (10).
Selecting the most appropriate analytical methods 
is often not easy and the choice depends on the 
availability of staP , expertise and equipment, the 
nature of the service to be provided and the range 
of drugs to be assayed.
The major advantage of chromatographic tech-
niques is their b exibility and adaptability to a wide 
range of drugs. However, in comparison to immu-
noassays they are slow, labour-intensive techniqu-
es which usually demand a high degree of techni-
cal expertise. Immunoassays have higher develo-
pment cots than chromatography, narrow range 
of drugs to be analysed and are generally more 
susceptible to interference to endogenous com-
ponents (cross-reactivity) (11).
The objective of our study was to investigate the 
interchangeability of immunoassay and chroma-
tography for the quantitative measurement of CBZ 
and PHT and to investigate whether measure-
ments in two labs using diP erent HPLC systems 
could results in diP erences in the determination of 
CBZ and PHT in same serum samples. Additionally 
we investigated the relation between the serum 
concentrations of CBZ and its metabolite, CBZ-E.
Materials and methods
This retrospective study was carried out on 102 
blood samples collected from epileptic outpatients 
who were referred for routine TDM in the IMD lab-
Berlin (Institute for Medical Diagnosis, Berlin, Ger-
many). Serum concentrations of CBZ were deter-
mined in 72 samples, while the concentrations of 
PHT were determined in 30 serum samples. Blood 
samples were taken at steady state concentration of 
these drugs. The serum concentrations of CBZ and 
its metabolite CBZ-E and PHT were determined 
comparatively by two HPLC systems, HPLC 1 and 
HPLC 2 (HPLC 1: model Shimadzu LC-9A in the Insti-
tute of Clinical Pharmacology of University Clinical 
Center “Charite”, Berlin; HPLC 2: model Agilent 1050 
HPLC-System in the Institute for Medical Diagnosis-
IMD Berlin). In both institutions measurements of 
AED are established for routine TDM.
In the HPLC 1 we used the commercial available kit 
for determination of AED (Chromsystems Instru-
ments & Chemicals GmbH, München, Germany). 
We used other components of kit: Mobile Phase, 
high resolution, 1000 mL; AED Serum calibration 
standard; Internal standard, 15 mL and Precipitati-
on reagent, 5 mL. We performed a sample prepa-
ration as was described in the manual of manufac-
turer. The HPLC 1 parameters were:
isocratic HPLC system with UV detector;• 
injection volume 20 µL;• 
b ow rate: high resolution, 1.2 mL/min;• 
wavelength: 204 nm;• 
column temperature ambient (~25 °C).• 
We have used a column and precolumn of Chrom-
systems Instruments & Chemicals GmbH.
In the HPLC 2 we used a ClinRep® Complete Kit for 
AED in serum (order no. 15000; RECIPE Chemicals 
+ Instruments GmbH, München, Germany). The Kit 
components of ClinRep® were: Mobile phase 1000 
mL; Standard solution 3 mL; P Precipitant with in-
ternal standard IS 15 mL; Serum calibrator, lyop-
hylisate 3 mL; Sample preparation vials with rea-
gent (lyophilisate) and D diluting solution. The 
procedure of sample preparation was described in 
the manual of ClinRep® Complete Kit.
The HPLC 2 parameters were:
isocratic pump, b ow rate 1.0 mL/min;• 
10 µL injection volume;• 
injection interval 15 min;• 
UV/VIS Detector 205 nm;• 
HPLC-thermostat 55°C.• 
The concentration of CBZ and PHT of the same pa-
tient’s samples were determined consecutively by 
bench top immunoassay analyzer (Model MGC 240 
Microgenics – Fisher ScientiW c, Passau, Germany). 
We used a Carbamazepine kit (CEDIA) and Phe-
nytoine kit (CEDIA) and Biorad controls (Immunoa-
ssay Plus Control – Lyphocheck level 1, and Lypho-
check level 2). The calibration stability (Cedia® Core 
TDM Multi calibrator) was controlled by daily 
running of controls to check the intra assay speciW -
ty. Between run coeu  cients of variation were < 8% 
for all assays in two HPLC analytical systems. Se-
rum samples were stored at -20 °C. The statistical 
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analysis of relations between HPLC and immuno-
assay results was performed with Microsoft EXCEL® 
software (Analyse-it®), using the linear regression 
analysis and Passing-Bablok method and Bland-
Altman plots (12).
For presentation of relation between the CBZ and 
CBZ-E we used parametric tests when the data had 
a Gaussian distribution (Student-t test and Pearson 
correlation coeu  cient) (13).
Results
Analysis of the results revealed that the compli-
ance of serum concentrations of CBZ and PHT be-
tween immunoassay and HPLC and between two 
diP erent HPLC (HPLC 1 and 2) is very good. We ob-
served excellent correlation (r = 0.97, P < 0.001) be-
tween CBZ concentrations obtained by HPLC 1 
and CEDIA (Figure 1a). The same correlation (r = 
0.97, P < 0.001) of CBZ concentrations were found 
between HPLC 2 and CEDIA (Figure 1b). In the anal-
ysis of compliance between the two HPLC systems 
in determination of CBZ concentrations, we ob-
tained even better correlation, r = 0.99, P < 0.001 
(Figure 1c).
FIGURE 1A. The comparison of serum concentration of CBZ be-




































































r = 0.97; 95% CI =0.95-0.95
P < 0.001
FIGURE 1B. The comparison of serum concentration of CBZ be-

































r = 0.99; 95% CI =0.98 to 0.99
P < 0.001
FIGURE 1C. The comparison of serum concentration of CBZ be-
tween HPLC 1and HPLC 2
Likewise correlations were obtained for PHT serum 
concentration for diP erent analytical methods. 
The good correlation of PHT serum concentration 
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Passing and Bablok ; t comparison 95% CI
Method Comparison n Range (µmol/L) Passing and Bablok ; t Constant Proportional
HPLC 1 vs. CEDIA (CBZ) 72 6.19–42.84 0.81 + 1.00x –0.14–2.01 0.94–1.07
HPLC 2 vs. CEDIA (CBZ) 72 6.19–42.84 0.29 + 1.03x –0.90–1.58 0.97–1.10
HPLC 1 vs. HPLC 2 (CBZ) 72 7.73–42.84 –0.33 + 1.02x –1.19–1.06 0.98–1.06
HPLC 1 vs. CEDIA (PHT) 30 4.58–125.82 0.07 + 1.02x –1.66–1.45 0.97–1.09
HPLC 2 vs. CEDIA (PHT) 30 4.58–125.82 –0.08 + 1.05x –2.30–2.46 0.96–1.15
HPLC 1 vs. HPLC 2 (PHT) 30 6.11–118.28 0.04 + 1.00x –1.95–1.86 0.94–1.06
HPLC1 vs. HPLC 2 (EPO–CBZ) 72 0.53–9.51 –0.08 + 0.82x –0.41–0.19 0.73–0.93
TABLE 1. Passing and Bablok Fit Comparison of CBZ, PHT and EPO-CBZ serum concentrations measured by HPLC 1, HPLC 2 and CEDIA 
Immunoassay (µmol/L).
between HPLC 1 and CEDIA (r = 0.98, P < 0.001) and 
between HPLC 2 and CEDIA (r = 0.98, P < 0.001) is 
presented in W gure 2a and 2b, respectively. Com-
parison of PHT serum concentrations obtained by 
two diP erent HPLC (HPLC 1 and 2) in two diP erent 
labs also showed very good correlation (r = 0.98, P 
< 0.001) (Figure 2c).
In addition possible diP erences between two dif-
ferent HPLC systems were further evaluated by 
comparison of correlations between CBZ and its 
metabolite, EPO-CBZ. The correlation coeu  cients 
between CBZ and EPO-CBZ measured by HPLC in 
two diP erent labs are shown in the Figure 3a and 
3b. The correlations between CBZ and EPO-CBZ in 
both HPLC systems were moderate, i.e. r = 0.486 (P 
< 0.001) for HPLC 1 and r = 0.427 (P < 0.001) for 
HPLC 2. The correlation between HPLC 1 and HPLC 
2 in measurement of EPO-CBZ was good (R = 0.88, 
P < 0.001).
In order to compare two analytical methods and 
two HPLC using diP erent commercial kit we appli-
ed the comparison by Passing-Bablok method. 
The detail results between diP erent HPLC (HPLC 1 
and HPLC 2) and between HPLC and immunoassay 
we have presented in table 1.
The agreement between HPLC 1 and HPLC 2 in the 
determination of CBZ, PHT and CBZ-E we have eva-
luated through Bland-Altman agreement. This 
method we used to compare the immunoassay 
and chromatographic method (HPLC 1 and HPLC 
2) and to present diP erence vs. mean average (Fi-
gure 4a-c; 5a-c and 6a). The results of Passing Ba-
blok comparison are presented in the table 1.
Discussion
TDM as routine service includes the measurement 
of serum concentrations of numerous drugs pre-
senting widely varying chemical structures. Thus, 
in the TDM service a compromise has to be made 
between using the best method for each individu-
al analyte and using the techniques that allow 
quantization of wide range of substances.
In our study besides the correlation between two 
analytical methods (immunoassay-CEDIA and 
HPLC), we attempt to present the impact of diP er-
ent HPLC systems with diP erent procedures of vali-
dation. The correlation between two HPLC systems 
and correlation between two HPLC methods and im-
munoassay method (CEDIA) observed in the pres-
ent study proved very satisfactory for CBZ and PHT.
The correlation coeu  cient of serum concentration 
of CBZ and PHT between the HPLC 1 and CEDIA in 
our study were the same (each r = 0.974), while the 
correlations of serum concentrations of CBZ and 
PHT between the HPLC 2 and CEDIA in our study 
were slightly diP erent (r = 0.969 and r = 0.990). The 
above W ndings almost match results of Rambeck 
et al., who found that in the case of PHT there was 
a highly linear correlation (r = 0.985, y = 1.113x - 
0.589) between HPLC and the Biotrack system, 
while in the case of CBZ, the correlation between 
HPLC and Biotrack system was somewhat lower (r 
= 0.931, y = 1.29x - 0.136) (14). Similar results of cor-
relation have found others authors, too (15,16).
In contrast to immunoassay, the TDM of CBZ using 
the chromatography system enables to measure 
the concentrations of CBZ-E. The determination of 
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r = 0.98; 95% CI =0.95–0.99
P < 0.001
FIGURE 2A. The comparison of serum concentration of PHT be-
































r = 0.98; 95% CI =0.96–0.99
P < 0.001
FIGURE 2B. The comparison of serum concentration of PHT be-





























r = 0.98; 95% CI =0.96–0.99
P < 0.001
FIGURE 2C. The comparison of serum concentration of PHT be-
tween HPLC 1 and HPLC 2
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FIGURE 3A. Comparison between serum concentration of CBZ 
and CBZ-E: HPLC 1
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FIGURE 3B. Comparison between serum concentration of CBZ 
and CBZ-E: HPLC 2
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FIGURE 3C. Comparison between serum concentration of EPO-
CBZ (HPLC 1) and EPO-CBZ (HPLC 2)





























































































95% Limits of agreement
(–2.668 to 4.674)
FIGURE 4B. Bland-Altman plot: DiP erence HPLC2 vs. CEDIA (CBZ)
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95% Limits of agreement
(–2.315 to 2.424)
FIGURE 4C. Bland-Altman plot: DiP erence HPLC1 vs. HPLC2 (CBZ)















































FIGURE 5A. Bland-Altman plot: DiP erence HPLC1 vs. CEDIA (PHT)

















































FIGURE 5B. Bland-Altman plot: DiP erence HPLC2 vs. CEDIA (PHT)


















































FIGURE 5C. Bland-Altman plot: DiP erence HPLC1 vs. HPLC2 (PHT)
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CBZ-E presents an advantage in TDM concerning 
the fact that this metabolite has similar pharmaco-
logical activity to the parent drug (17,18), and this 
should be considered in the optimization of CBZ 
therapy (19). In our study we noted the moderate 
correlation between CBZ and CBZ-E level deter-
mined by HPLC 1 (r = 0.486) and HPLC 2 (r = 0.427). 
Previous authors conW ned the variability of corre-
lation between the CBZ and its metabolite, CBZ-E. 
Mihaly et al. presented moderate correlation coef-
W cient of plasma concentrations of CBZ and its me-
tabolite, CBZ-E (r = 0.495) (20). Mihaly suggested 
that there was a considerable inter-subject varia-
tion in the metabolism of CBZ to CBZ-E, without 
presenting any other possible factor. Semah et al. 
observed correlation between CBZ and CBZ-E pla-
sma levels found in the mono-therapy group, but 
not in the poly-therapy group (21). Further we 
found a good correlation in determination of CBZ-E 
serum concentration between HPLC 1 and HPLC 2.
Unfortunately, in our study were not able to deter-
mine which serum samples present mono-therapy 
or poly-therapy of CBZ.
Pasing-Bablok regression and Altman – Bland plots 
supported the comparison between two diP erent 
HPLC and between chromatography and immu-
noassay. The Bland-Altman scatter diagram 
showed the diP erences plotted against the avera-
ges of the two measurements, drawing the mean 
diP erence, and the limits of agreement, deW ned as 
the mean diP erence plus and minus 1.96 times the 
standard deviation of the diP erences. The results 
showed the good agreement between diP erent 
measurement techniques.
Conclusion
The correlation between 2 analytical methods and 
between 2 HPLC systems is very good indicating 
the complementarities of results of TDM in both 
institutions.
The moderate correlation between CBZ and CBZ-E 
obtained in our study by both HPLC systems show 
the possible implication of other pharmacokinetic 
factors and possible concomitant AED that was 
not subject of investigation in this study. The ana-
lytical determination of CBZ-E could be advantage 
of chromatography in comparison with CEDIA im-
munoassay.
FIGURE 6A. Bland-Altman plot: DiP erence HPLC1 vs. HPLC2 
(EPO-CBZ)
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Usporedba imunokemijske metode i metode tekućinske kromatogra; je 
visoke djelotvornosti u terapeutskom promatranju karbamazepina i fenitoina
Sažetak
Uvod: Cilj je bio istražiti korelaciju imunokemijske i kromatografske metode u kvantitativnom mjerenju dva antiepileptična lijeka, karbama-
zepina (CBZ) i fenitoina (PHT) te ustanoviti povezanost između CBZ i njegovog metabolita karbamazepin 10,11-epoksida (CBZ-E). Dodatno smo 
istražili metodom tekućinske kromatograO je visoke djelotvornosti (engl. high performance liquid chromatography, HPLC) bi li postojale razlike u 
određivanju koncentracije CBZ i PHT u serumu kad bi se mjerenje vršilo u dva različita laboratorija.
Materijali i metode: Ovo je istraživanje provedeno na 102 uzorka krvi (72 za CBZ i 30 za PHT) sakupljenih od bolesnika s epilepsijom. Koncen-
tracije CBZ i PHT u plazmi određene su validiranom metodom HPLC (na sistemima Shimadzu i Agilent) te imunokemijskom metodom CEDIA.
Rezultati: Korelacija koncentracija CBZ u serumu između metode CEDIA i metode HPLC 1 te između metode CEDIA i metode HPLC 2 bile je dobra 
(r = 0,97 za obje tehnike). Još je bolja korelacija izračunata između koncentracija CBZ izmjerenih na dva HPLC sistema (r = 0,99). Slično je bilo i za 
PHT. Izračunali smo dobru korelaciju između metode CEDIA i dva sistema metode HPLC (HPLC 1 i HPLC 2; r = 0,98) te između dva sistema metode 
HPLC r = 0,98. KoeO cijent korelacije između koncentracije CBZ u serumu i koncentracije njegovog metabolita CBZ-E izmjerenih u dva laboratorija 
primjenom različitih metoda HPLC iznostio je r = 0,49 za CBZ i r = 0,43 za CBZ-E, pri čemu je P < 0,001.
Zaključak: Pratili smo dobru korelaciju za određivanje koncentracije CBZ i PHT primjenom imunokemijske metode i metodom HPLC na dva razli-
čita sistema. Mogućnost mjerenja CBZ-E predstavlja prednost kromatograO je pred imunokemijskom metodom.
Ključne riječi: karbamazepin; fenitoin; HPLC; imunokemijska metoda
